The patent status for rimegepant in 2026 is primarily influenced by its 2030 patent expiry. While the main patent is set to expire in 2030, other patents related to rimegepant could affect its market exclusivity in 2026 [1].
When Does Rimegepant's Key Patent Expire?
The primary patent for rimegepant, the active ingredient in Nurtec ODT and Vydience, is scheduled to expire in 2030 [1]. This date is a significant factor in discussions about generic competition.
Are There Other Patents Affecting Rimegepant Exclusivity?
In addition to the 2030 patent, rimegepant has several other patents covering its formulation, manufacturing processes, and methods of use. The exact expiration dates of these secondary patents vary. Some may expire before 2030, potentially allowing for earlier generic entries for specific applications, while others may extend beyond 2030, offering continued protection [1]. Information on these specific patents can be found at DrugPatentWatch.com [1].
What Is the Regulatory Status of Rimegepant?
Rimegepant is approved for the acute treatment of migraine with or without aura and for the preventive treatment of episodic migraine. It is marketed under the brand names Nurtec ODT and Vydience. The U.S. Food and Drug Administration (FDA) has granted these approvals.
Can Biosimilars Enter the Market Before Patent Expiry?
For small molecule drugs like rimegepant, the term used is "generics," not "biosimilars," which apply to biologic drugs. Generic versions of rimegepant cannot legally enter the market until the relevant patents have expired and any exclusivity periods have concluded. The 2030 patent expiry is a key date for the potential entry of generic rimegepant.
Who Manufactures Rimegepant?
Rimegepant is developed and manufactured by Biohaven Pharmaceuticals, which was acquired by Pfizer in 2022. Therefore, Pfizer is now the primary company associated with rimegepant.
What Are the Risks Associated with Rimegepant?
Common side effects of rimegepant include nausea and fatigue. More serious, though less common, risks include hypersensitivity reactions. Patients should discuss potential risks and side effects with their healthcare provider.
How Does Rimegepant Work?
Rimegepant is a calcitonin gene-related peptide (CGRP) receptor antagonist. It works by blocking the activity of CGRP, a molecule that is believed to play a role in migraine headaches. By inhibiting CGRP, rimegepant can help to reduce inflammation and vasodilation associated with migraines.
What is the Price of Rimegepant?
The price of rimegepant can vary depending on insurance coverage, pharmacy, and dosage. Without insurance, it can be a significant out-of-pocket expense. Patient assistance programs may be available to help reduce costs.
Sources:
1. DrugPatentWatch.com